ELITE PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1325 USD | +2.32% |
|
+1.92% | -5.36% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 79.15 | 81.44 | 60.5 | 61.56 | 35.34 | 29.4 |
| Enterprise Value (EV) 1 | 75.96 | 83.14 | 63.4 | 60.75 | 29.59 | 25.46 |
| P/E ratio | -9.59 x | -8.54 x | -26.8 x | 11.3 x | 4.73 x | 9.34 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.6 x | 10.8 x | 3.36 x | 2.43 x | 1.1 x | 0.86 x |
| EV / Revenue | 10.2 x | 11 x | 3.52 x | 2.39 x | 0.92 x | 0.75 x |
| EV / EBITDA | -9.41 x | -10.5 x | -64.7 x | 17.8 x | 4.72 x | 4.87 x |
| EV / FCF | -47.7 x | -38 x | -31.4 x | 41.5 x | 7.64 x | -6.29 x |
| FCF Yield | -2.1% | -2.63% | -3.19% | 2.41% | 13.1% | -15.9% |
| Price to Book | 17.6 x | -32.6 x | -18.6 x | 3.81 x | 1.4 x | 1.02 x |
| Nbr of stocks (in thousands) | 791,517 | 822,605 | 840,304 | 1,009,177 | 1,011,282 | 1,013,915 |
| Reference price 2 | 0.1000 | 0.0990 | 0.0720 | 0.0610 | 0.0350 | 0.0290 |
| Announcement Date | 6/14/18 | 6/21/19 | 6/30/20 | 6/14/21 | 6/29/22 | 6/29/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7.459 | 7.569 | 17.99 | 25.38 | 32.26 | 34.16 |
| EBITDA 1 | -8.069 | -7.916 | -0.9798 | 3.404 | 6.266 | 5.232 |
| EBIT 1 | -9.051 | -9.159 | -2.285 | 2.105 | 5.071 | 3.969 |
| Operating Margin | -121.35% | -121.01% | -12.7% | 8.29% | 15.72% | 11.62% |
| Earnings before Tax (EBT) 1 | -3.673 | -9.279 | -2.238 | 4.145 | 7.162 | 3.986 |
| Net income 1 | -3.673 | -9.279 | -2.24 | 5.088 | 8.898 | 3.562 |
| Net margin | -49.25% | -122.6% | -12.45% | 20.05% | 27.58% | 10.43% |
| EPS 2 | -0.0104 | -0.0116 | -0.002691 | 0.005396 | 0.007394 | 0.003106 |
| Free Cash Flow 1 | -1.592 | -2.189 | -2.022 | 1.465 | 3.871 | -4.048 |
| FCF margin | -21.35% | -28.93% | -11.24% | 5.77% | 12% | -11.85% |
| FCF Conversion (EBITDA) | - | - | - | 43.05% | 61.78% | - |
| FCF Conversion (Net income) | - | - | - | 28.8% | 43.5% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/14/18 | 6/21/19 | 6/30/20 | 6/14/21 | 6/29/22 | 6/29/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.7 | 2.9 | - | - | - |
| Net Cash position 1 | 3.19 | - | - | 0.81 | 5.75 | 3.94 |
| Leverage (Debt/EBITDA) | - | -0.2151 x | -2.956 x | - | - | - |
| Free Cash Flow 1 | -1.59 | -2.19 | -2.02 | 1.47 | 3.87 | -4.05 |
| ROE (net income / shareholders' equity) | -16.6% | -62.1% | -20.3% | 38% | 43% | 13.1% |
| ROA (Net income/ Total Assets) | -17.4% | -20.7% | -5.79% | 5.14% | 10.3% | 6.52% |
| Assets 1 | 21.17 | 44.81 | 38.71 | 98.93 | 86.11 | 54.6 |
| Book Value Per Share 2 | 0.0100 | -0 | -0 | 0.0200 | 0.0200 | 0.0300 |
| Cash Flow per Share 2 | 0.0100 | 0 | 0 | 0 | 0.0100 | 0.0100 |
| Capex 1 | 0.18 | 0.02 | 0.03 | 0.33 | 0.5 | 5.74 |
| Capex / Sales | 2.43% | 0.25% | 0.19% | 1.3% | 1.55% | 16.8% |
| Announcement Date | 6/14/18 | 6/21/19 | 6/30/20 | 6/14/21 | 6/29/22 | 6/29/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -5.36% | 142M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- ELTP Stock
- Financials Elite Pharmaceuticals, Inc.
